Introduction {#ss1}
============

Diabetic autonomic neuropathy is a major complication in patients with diabetes; it decreases quality of life and increases mortality. Long‐term hyperglycemia is a primary cause of diabetic neuropathy[^1^](#b1){ref-type="ref"}. Conversely, autonomic function might affect glycemic control through gastrointestinal peristalsis. In addition, results from animal experiments have suggested that the autonomic nervous system contributes to glucose homeostasis by mediating interorgan networks[^2--4^](#b2 b3 b4){ref-type="ref"}. Matsuhisa *et al.* have reported that the vagus nerve, which in part controls the liver, plays an important role in regulating postprandial glucose levels[^5,6^](#b5 b6){ref-type="ref"}. In addition, the intestinal--brain--liver neuronal axis has been reported to be involved in liver gluconeogenesis[^4^](#b4){ref-type="ref"}. However, evidence showing that these pathways and autonomic function play a role in glycemic control is lacking in humans. The aim of the present study was to examine whether there is a relationship between autonomic function, evaluated by coefficient of variation of the R‐R interval on electrocardiograms (ECG; CVRR), and post‐challenge hyperglycemia in patients with newly diagnosed type 2 diabetes.

Material and methods {#ss2}
====================

Subjects {#ss3}
--------

A total of 122 Japanese patients newly diagnosed with type 2 diabetes mellitus between January 2008 and December 2009, in the Division of Endocrinology and Metabolism at Kanazawa University Hospital, were recruited for the present study. None of the patients were treated with an oral hypoglycemic agent or insulin. [Table 1](#t1){ref-type="table-wrap"} shows the demographic, clinical and physical characteristics of the subjects.

######  Clinical characteristics of the 74 newly diagnosed type 2 diabetic patients

  Clinical parameters              Value
  -------------------------------- --------------
  Age (years)                      60.1 ± 11.1
  Sex (male/female)                 82/40
  Body mass index (kg/m^2^)        25.1 ± 4.7
  Fasting plasma glucose (mg/dL)   139.9 ± 31.8
  HbA~1c~ (%) (JDS)                7.9 ± 2.0

  Diabetic complications    *n*      Prevalence (%)
  ------------------------- -------- ----------------
  Retinopathy (Fukuda†*)*            
   0                        88/112   79
   A1                       7/112    6
   A2                       6/112    5
   A3                       4/112    3
   B1                       2/112    2
   B4                       5/112    4
  Nephropathy                        
   Stage 1                  90/120   75
   Stage 2                  19/120   16
   Stage 3a                 7/120    6
   Stage 3b                 3/120    3
   Stage 4                  1/120    1
  Somatic polyneuropathy‡   17/95    18

Data are means ± SD. JDS, Japan Diabetes Society. †Retinopathy stages were diagnosed according to Fukuda's classification (Fukuda M. Classification and treatment of diabetic retinopathy. *Diabetes Research and Clinical Practice*. 1994; 24 Suppl: s171--s176) as follows: Stage 0, patients without retinopathy; Stage A1, mild to moderate simple retinopathy; Stage A2, severe simple retinopathy; Stage A3, mild to moderate interrupted proliferative retinopathy; Stage A4, 5, severe interrupted proliferative retinopathy; Stage B1, pre‐proliferative diabetic retinopathy; Stage B2, early proliferative diabetic retinopathy; Stage B3, advanced proliferative diabetic retinopathy; Stage B4, end‐stage proliferative diabetic retinopathy. ‡Somatic polyneuropathy was defined as below mean‐2SD in nerve conduction velocity in two or more of six sites in the healthy subject.

Written informed consent was obtained from all patients before initiation of the study. The study was approved by the ethics committee established at the Kanazawa University Hospital (Approval No. 729) and was carried out in accordance with the Declaration of Helsinki.

Laboratory Data {#ss4}
---------------

HbA~1c~ was described in the Japan Diabetes Society (JDS) value. Oral glucose tolerance tests using 75 g of glucose (75‐g OGTT) were carried out for all patients. The plasma glucose concentration was measured using an automated glucose analyzer (model GA08; ATWiLL M.I., Kanazawa, Japan). The plasma insulin concentration was measured by immunoassay (AIA‐1800ST; Tosoh, Tokyo, Japan).

Insulin resistance in the liver was evaluated using the liver insulin resistance index (L‐IR) as reported by Muhammad *et al.*[^7^](#b7){ref-type="ref"}. Insulin resistance in muscle was evaluated using the muscle insulin resistance index (M‐IR) as reported by Matsuda *et al.*[^8^](#b8){ref-type="ref"}. To evaluate initial insulin secretion, the insulinogenic index was calculated by dividing the change in immunoreactive insulin (IRI) over 30 min by the change in plasma glucose (PG) over 30 min: ΔIRI (30′ -- 0′) μU/mL/ΔPG (30′ -- 0′) mg/dL.

Evaluation of Autonomic Nerve Function {#ss5}
--------------------------------------

The CVRR was used to evaluate diabetic autonomic neuropathy[^9^](#b9){ref-type="ref"}. After the patient had rested in the supine position for at least 10 min, a standard 12‐lead ECG was recorded (Cardio Star FCP‐7541; Nihon Kohden, Tokyo, Japan). The R‐R intervals were measured for 3 min, and the CVRR was obtained by dividing the standard deviations (SD) by the means (M): CV (%) = (SD/M) × 100. Because CVRR is influenced by age, we also used CVRR *Z*‐score calculated by (CVRR‐mean CVRR)/SD‐CVRR in each age category to the age‐specific normal value of CVRR (Table S2).

Statistical Analysis {#ss6}
--------------------

For statistical analyses, SPSS II for Windows (SPSS, Chicago, IL, USA) was used. Single regression analysis and multiple regression analysis were used to examine associations between CVRR and clinical parameters. All data are presented as means ± SD.

Results {#ss7}
=======

Clinical characteristics of the 122 newly diagnosed type 2 diabetic patients are shown in [Table 1](#t1){ref-type="table-wrap"}. The prevalence of retinopathy and nephropathy was 21% and 25% of the subjects, respectively. When somatic polyneuropathy is defined as below mean‐2SD in nerve conduction velocity in more than two of six sites in the healthy subjects, its prevalence was 18%.

The results for single linear regression analyses between CVRR and each clinical parameter are shown in [Table 2](#t2){ref-type="table-wrap"}. CVRR was significantly correlated with age (*r* = −0.209, *P* \< 0.021) and PG120 (*r* = −0.219, *P* \< 0.015; [Table 2](#t2){ref-type="table-wrap"}), but was not correlated with body mass index, HbA~1c,~ insulinogenic index, PG0‐60 and IRI0‐120, L‐IR, and M‐IR (*P* \> 0.05; [Table 2](#t2){ref-type="table-wrap"}). Although CVRR diminishes with age, CVRR, but not age, significantly correlated to PG120 (Table S1). In a multiple regression analysis for PG 120 as a dependent variable, CVRR was still significantly correlated with PG120 (*P* = 0.004), even after adjustment for age ([Table 3](#t3){ref-type="table-wrap"}, upper panel). When we used CVRR *Z*‐scores in the analysis, CVRR Z score, but not age, was significantly correlated with PG120 in a multiple regression model ([Table 3](#t3){ref-type="table-wrap"}, lower panel).

######  Single linear regression analyses between coefficients of variation of the R‐R intervals on electrocardiograms and clinical parameters

  Variable              *r*‐value   *P*‐value
  --------------------- ----------- -----------
  Age                   −0.209      0.021\*
  BMI                   0.188       0.075
  HbA~1c~ (JDS)         0.057       0.536
  Insulinogenic index   0.014       0.902
  PG0                   −0.054      0.554
  PG30                  0.041       0.650
  PG60                  −0.108      0.236
  PG120                 −0.219      0.015\*
  IRI0                  −0.114      0.211
  IRI30                 −0.021      0.817
  IRI60                 0.002       0.978
  IRI120                0.024       0.794
  L‐IR                  0.042       0.718
  M‐IR                  −0.182      0.121

\**P* \< 0.05. PG0, plasma glucose concentration before load; PG30, plasma glucose concentrations at 30 min after load; PG60, plasma glucose concentrations at 60 min after load; PG120, plasma glucose concentrations at 120 min after load; IRI0, immunoreactive insulin before load; IRI30, immunoreactive insulin at 30 min after load; IRI60, immunoreactive insulin at 60 min after load; IRI120, immunoreactive insulin at 120 min after load; L‐IR, liver insulin resistance index; M‐IR, muscle insulin resistance index.

######  Multiple regression analysis for plasma glucose concentrations at 120 min after load as a dependent variable and clinical parameters as independent variables

                   Partial regression coefficient β   *t*‐value   *P*‐value
  ---------------- ---------------------------------- ----------- -----------
  Sex              −12.061                            −1.135      0.259
  Age              −1.109                             −1.994      0.048\*
  CVRR             −16.879                            −2.901      0.004\*
  Sex              −12.091                            −1.143      0.255
  Age              −0.534                             −0.924      0.357
  CVRR *Z*‐score   −18.123                            −2.935      0.004\*

CVRR, coefficients of variation of the R‐R intervals on electrocardiograms. \**P* \< 0.05; *n* = 121.

Discussion {#ss8}
==========

The preset results suggest that autonomic nerve dysfunction, specifically parasympathetic nerve dysfunction, increases post‐challenge glucose levels without affecting insulin secretion or insulin sensitivity. One possible mechanism underlying autonomic dysfunction‐associated post‐challenge hyperglycemia is gastrointestinal peristalsis that affects absorption of nutrients[^10^](#b10){ref-type="ref"}.

The failure of liver gluconeogenesis, regulated by the vagus nerve, has been shown to contribute to diabetic autonomic neuropathy‐related hyperglycemia. Wang *et al.*[^4^](#b4){ref-type="ref"} reported that lipids in the upper intestine activate the intestine--brain--liver neural axis to inhibit glucose production. This mechanism, which inhibits liver gluconeogenesis after food consumption, is mediated through the vagus nerve, which innervates the small intestine from the cerebrum. We suspect that dysfunction of this mechanism caused by diabetic autonomic neuropathy might contribute to hyperglycemia.

The neuronal pathway might mediate the action of incretin hormones secreted by the gut, such as glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent gastric inhibitory peptide (GIP). Incretin hormones enhance glucose‐mediated insulin secretion and suppress exaggerated glucagon secretion[^11--14^](#b11 b12 b13 b14){ref-type="ref"}, thereby regulating postprandial plasma glucose levels.

Diabetic autonomic neuropathy might also cause the dysfunction of cardiovascular, gastrointestinal, genitourinary, sudomotor or ocular organs[^1^](#b1){ref-type="ref"}. Postprandial and post‐challenge hyperglycemia is an independent risk factor for macrovascular disease[^15--17^](#b15 b16 b17){ref-type="ref"} as well as many other complications, such as diabetic retinopathy[^18^](#b18){ref-type="ref"}, increased carotid intima‐media thickness[^19^](#b19){ref-type="ref"}, increased oxidative stress[^20^](#b20){ref-type="ref"}, decreased myocardial blood volume and myocardial blood flow[^21^](#b21){ref-type="ref"}, increased risk for cancer[^22^](#b22){ref-type="ref"}, and impaired cognitive function[^23^](#b23){ref-type="ref"}. Further studies are needed to clarify whether diabetic autonomic neuropathy increases the risks for these complications.

In conclusion, the present results suggest that autonomic function affects post‐challenge blood glucose levels independently of age in patients with type 2 diabetes.
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